Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib for Leptomeningeal Carcinomatosis in EGFR+ NSCLC
NCT00830245Phase 2Terminated
- Sponsor
- Clinical Research Center for Solid Tumor
- Start
- Jan 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib in leptomeningeal carcinomatosis (LMC) and non-small cell lung cancer (NSCLC), sponsored by Clinical Research Center for Solid Tumor. Primary endpoint: Overall Survival at 1 year. Started Jan 2009; status: terminated.
02
Drugs
erlotinib
03
Conditions
leptomeningeal carcinomatosis (LMC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00830245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00830245.